NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 53.98

-6.5%

Nov 13 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (201)	3/13/2007 5:51:20 PM
From: david nordic	Read Replies (1) of 507

Nektar starts early trial of cancer treatment Tuesday March 13, 4:39 pm ET Nektar Therapeutics said Tuesday it has started a Phase I clinical trial to measure the safety and effectiveness of a potential cancer treatment. The San Carlos company (NASDAQ: NKTR - News) is testing the drug, NKTR-102, as a possible treatment for people with refractory solid tumors. Refractory cancer is resistant to treatment. Nektar seeks to make the treatment more effective by increasing the time the drug circulates in the bloodstream. This treatment is a formulation of the widely used anti-cancer drug irinotecan modified using Nektar's technology. Published March 13, 2007 by San Francisco Business Times

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next